Jazz Pharmaceuticals plc(JAZZ)Earnings, Financials & Key Ratios

JAZZ•NASDAQ

$212.26

$13.32B mkt cap·Price updated May 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Specialty Pharma

AboutJazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.Show more

Revenue$4.27B+4.9%
EBITDA$766M-44.3%
Net Income-$356M-163.6%
EPS (Diluted)-5.84-167.5%
Gross Margin88.21%-0.9%
EBITDA Margin17.96%-46.9%
Operating Margin5.26%-70.1%
Net Margin-8.35%-160.6%
ROE-8.47%-159.2%
ROIC2.08%-69.3%
Debt/Equity1.26-16.6%
Interest Coverage-2.22-161.4%

Analysis→Technical→

JAZZ Key Insights

Jazz Pharmaceuticals plc (JAZZ) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓FCF machine: 30.4% free cash flow margin
✓Momentum leader: RS Rating 82 (top 18%)
✓Strong 5Y sales CAGR of 12.5%
✓Share count reduced 7.6% through buybacks
✓Trading near 52-week high

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

JAZZ Price & Volume

Jazz Pharmaceuticals plc (JAZZ) stock price & volume — 10-year historical chart

Loading chart...

JAZZ Growth Metrics

Jazz Pharmaceuticals plc (JAZZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years12.41%

5 Years12.54%

3 Years5.26%

TTM9.2%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-93.88%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-98.53%

Return on Capital

10 Years7.31%

5 Years3.26%

3 Years4.98%

Last Year2.2%

JAZZ Recent Earnings

Jazz Pharmaceuticals plc (JAZZ) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (42%)

Q1 2026Latest

Feb 24, 2026

EPS

$6.64

Est $6.52

+1.8%

Revenue

$1.2B

Est $1.2B

+2.8%

Q4 2025

Nov 5, 2025

EPS

$8.13

Est $5.95

+36.6%

Revenue

$1.1B

Est $1.1B

+1.3%

Q3 2025

Aug 5, 2025

EPS

$8.25

Est $6.12

-34.8%

Revenue

$1.0B

Est $1.0B

-0.1%

Q2 2025

May 6, 2025

EPS

$1.68

Est $4.51

-62.7%

Revenue

$898M

Est $1.1B

-15.7%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 24, 2026	$6.64vs $6.52+1.8%	$1.2Bvs $1.2B+2.8%
Q4 2025	Nov 5, 2025	$8.13vs $5.95+36.6%	$1.1Bvs $1.1B+1.3%
Q3 2025	Aug 5, 2025	$8.25vs $6.12-34.8%	$1.0Bvs $1.0B-0.1%
Q2 2025	May 6, 2025	$1.68vs $4.51-62.7%	$898Mvs $1.1B-15.7%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
SUPNSupernus Pharmaceuticals, Inc.Direct Competitor	2.82B	49.03	-72.10	8.63%	-3.74%	-2.73%	1.63%	0.04
PCRXPacira BioSciences, Inc.Direct Competitor	975.11M	24.79	154.94	3.63%	1.27%	1.31%	14.01%	0.66
INVAInnoviva, Inc.Direct Competitor	1.69B	22.65	6.86	18.52%	65.38%	23.12%	11.58%
AVNSAvanos Medical, Inc.Direct Competitor	1.15B	24.70	-16.92	1.95%	-9.69%	-8.91%	3.74%	0.17
PRGOPerrigo Company plcDirect Competitor	1.6B	11.64	-1.13	-2.75%	-33.51%	-48.56%	9.06%	0.01
ALKSAlkermes plcProduct Competitor	6.12B	36.25	25.35	-5.25%	16.37%	14.45%	7.85%	0.04
INCYIncyte CorporationProduct Competitor	19.47B	97.47	15.21	21.22%	26.71%	29.31%	6.96%	0.01
HALOHalozyme Therapeutics, Inc.Product Competitor	7.76B	65.87	25.73	37.55%	22.69%	6.49%	8.31%

Compare JAZZ vs Peers

Jazz Pharmaceuticals plc (JAZZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SUPN

Most directly comparable listed peer for JAZZ.

Scale Benchmark

vs CVS

Larger-name benchmark to compare JAZZ against a more recognizable public peer.

Peer Set

Compare Top 5

vs SUPN, PCRX, INVA, AVNS

JAZZ Income Statement

Jazz Pharmaceuticals plc (JAZZ) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	1.62B	1.89B	2.16B	2.36B	3.09B	3.66B	3.83B	4.07B	4.27B	4.44B
Revenue Growth %	8.79%	16.82%	14.32%	9.34%	30.91%	18.26%	4.78%	6.12%	4.88%	9.2%
Cost of Goods Sold	110.19M	121.54M	127.93M	148.92M	440.76M	540.52M	435.58M	445.71M	503.3M	398.68M
COGS % of Revenue	6.81%	6.43%	5.92%	6.3%	14.24%	14.77%	11.36%	10.95%	11.79%	-
Gross Profit	1.51B▲ 0%	1.77B▲ 17.3%	2.03B▲ 14.9%	2.21B▲ 8.9%	2.65B▲ 19.8%	3.12B▲ 17.5%	3.4B▲ 9.0%	3.62B▲ 6.6%	3.76B▲ 3.9%	2.97B▲ 0%
Gross Margin %	93.19%	93.57%	94.08%	93.7%	85.76%	85.23%	88.64%	89.05%	88.21%	66.94%
Gross Profit Growth %	9.11%	17.29%	14.95%	8.89%	19.81%	17.54%	8.97%	6.61%	3.89%	-
Operating Expenses	979.66M	1.15B	1.5B	1.84B	2.48B	3.18B	2.82B	2.91B	3.54B	3.42B
OpEx % of Revenue	60.52%	61.06%	69.46%	77.7%	80.25%	87.02%	73.55%	71.43%	82.95%	-
Selling, General & Admin	544.16M	683.53M	736.94M	854.23M	1.45B	1.42B	1.34B	1.39B	1.81B	1.65B
SG&A % of Revenue	33.62%	36.15%	34.09%	36.14%	46.92%	38.72%	35.03%	34.05%	42.4%	-
Research & Development	198.44M	226.62M	299.73M	335.38M	505.75M	590.45M	849.66M	884M	782.74M	736.18M
R&D % of Revenue	12.26%	11.98%	13.86%	14.19%	16.34%	16.14%	22.16%	21.73%	18.34%	-
Other Operating Expenses	237.06M	244.39M	464.79M	646.97M	525.77M	1.18B	627.28M	637.31M	947.86M	2M
Operating Income	528.84M▲ 0%	614.84M▲ 16.3%	532.37M▼ 13.4%	378.07M▼ 29.0%	170.28M▼ 55.0%	-65.53M▼ 138.5%	578.58M▲ 983.0%	716.63M▲ 23.9%	224.42M▼ 68.7%	616.91M▲ 0%
Operating Margin %	32.67%	32.52%	24.63%	16%	5.5%	-1.79%	15.09%	17.61%	5.26%	13.9%
Operating Income Growth %	-10.62%	16.26%	-13.41%	-28.98%	-54.96%	-138.48%	982.95%	23.86%	-68.68%	-
EBITDA	694M	831.57M	902.53M	656.33M	722.76M	563.94M	1.22B	1.38B	766.42M	994.04M
EBITDA Margin %	42.87%	43.98%	41.75%	27.77%	23.36%	15.41%	31.75%	33.83%	17.96%	22.4%
EBITDA Growth %	-1.62%	19.82%	8.53%	-27.28%	10.12%	-21.97%	115.85%	13.1%	-44.33%	-20.86%
D&A (Non-Cash Add-back)	165.15M	216.73M	370.16M	278.25M	552.48M	629.47M	638.7M	660.07M	542M	377.13M
EBIT	613.84M	715.93M	642.35M	765.46M	475.26M	839.14M	810.73M	861.64M	-433.54M	-376.89M
Net Interest Income	-77.76M	-78.5M	-72.26M	-99.71M	-278.77M	-288.24M	-289.44M	-238.1M	-195.05M	-141.34M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	77.76M	78.5M	72.26M	99.71M	278.77M	288.24M	289.44M	238.1M	195.05M	101.44M
Other Income/Expense	-88.73M	-87.58M	-82.16M	-105.94M	-283.83M	-317.18M	-283.66M	-247.94M	-853.01M	-835.95M
Pretax Income	440.11M▲ 0%	527.26M▲ 19.8%	450.21M▼ 14.6%	272.13M▼ 39.6%	-113.55M▼ 141.7%	-382.7M▼ 237.0%	294.92M▲ 177.1%	468.69M▲ 58.9%	-628.59M▼ 234.1%	-219.04M▲ 0%
Pretax Margin %	27.19%	27.88%	20.83%	11.51%	-3.67%	-10.46%	7.69%	11.52%	-14.73%	-4.93%
Income Tax	-47.74M	80.16M	-73.15M	33.52M	216.12M	-158.65M	-119.91M	-91.43M	-272.44M	-248.53M
Effective Tax Rate %	-10.85%	15.2%	-16.25%	12.32%	-190.32%	41.45%	-40.66%	-19.51%	43.34%	113.46%
Net Income	487.85M▲ 0%	447.1M▼ 8.4%	523.37M▲ 17.1%	238.62M▼ 54.4%	-328.95M▼ 237.9%	-224.06M▲ 31.9%	414.83M▲ 285.1%	560.12M▲ 35.0%	-356.15M▼ 163.6%	29.49M▲ 0%
Net Margin %	30.14%	23.64%	24.21%	10.1%	-10.63%	-6.12%	10.82%	13.77%	-8.35%	0.66%
Net Income Growth %	22.94%	-8.35%	17.06%	-54.41%	-237.86%	31.89%	285.14%	35.02%	-163.58%	-93.88%
Net Income (Continuing)	487.85M	447.1M	523.37M	238.62M	-329.67M	-224.06M	414.83M	560.12M	-356.15M	29.49M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)	7.96▲ 0%	7.30▼ 8.3%	9.09▲ 24.5%	4.22▼ 53.6%	-5.51▼ 230.6%	-3.58▲ 35.0%	6.10▲ 270.4%	8.65▲ 41.8%	-5.84▼ 167.5%	0.45▲ 0%
EPS Growth %	24.18%	-8.29%	24.52%	-53.58%	-230.57%	35.03%	270.39%	41.8%	-167.51%	-98.53%
EPS (Basic)	8.13	7.45	9.22	4.28	-5.51	-3.58	6.55	9.06	-5.84	-
Diluted Shares Outstanding	61.32M	61.22M	57.55M	56.52M	59.69M	62.54M	72.07M	66.01M	60.98M	66.1M
Basic Shares Outstanding	60.02M	59.98M	56.75M	55.71M	59.69M	62.54M	63.29M	61.84M	60.98M	61.9M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

JAZZ Balance Sheet

Jazz Pharmaceuticals plc (JAZZ) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	968.28M	1.23B	1.63B	2.84B	2.61B	2.61B	3.44B	4.63B	4.17B	4.58B
Cash & Short-Term Investments	601.03M	824.62M	1.08B	2.13B	591.45M	881.48M	1.63B	2.99B	2.44B	1.84B
Cash Only	386.04M	309.62M	637.34M	1.06B	591.45M	881.48M	1.51B	2.41B	1.39B	1.84B
Short-Term Investments	215M	515M	440M	1.07B	0	0	120M	580M	1.05B	0
Accounts Receivable	224.13M	263.84M	355.99M	396.49M	563.36M	651.49M	705.79M	716.76M	830.75M	836.3M
Days Sales Outstanding	50.54	50.93	60.11	61.23	66.45	64.98	67.19	64.3	71.05	64.66
Inventory	43.24M	52.96M	78.61M	95.4M	1.07B	714.06M	597.04M	480.44M	416.96M	437.5M
Days Inventory Outstanding	143.25	159.03	224.28	233.82	888.34	482.19	500.3	393.44	302.39	421.73
Other Current Assets	76.69M	67.57M	78.89M	152.49M	252.39M	267.19M	320.81M	261.54M	476.44M	1.47B
Total Non-Current Assets	4.16B	3.97B	3.91B	3.7B	9.69B	8.23B	7.96B	7.38B	7.49B	7.28B
Property, Plant & Equipment	170.08M	200.36M	270.89M	257.1M	343.42M	301.38M	234.99M	227M	258.74M	258.9M
Fixed Asset Turnover	9.52x	9.44x	7.98x	9.19x	9.01x	12.14x	16.32x	17.93x	16.49x	17.48x
Goodwill	947.54M	927.63M	920.02M	958.3M	1.83B	1.69B	1.75B	1.72B	1.83B	1.8B
Intangible Assets	2.98B	2.73B	2.44B	2.2B	7.15B	5.79B	5.42B	4.76B	4.43B	4.2B
Long-Term Investments	0	0	0	0	0	0	0	4.33M	0	8.6M
Other Non-Current Assets	24.09M	52.28M	55.34M	30.96M	52.84M	64.39M	73.94M	119.64M	106.58M	440.67M
Total Assets	5.12B▲ 0%	5.2B▲ 1.6%	5.54B▲ 6.4%	6.54B▲ 18.0%	12.3B▲ 88.2%	10.84B▼ 11.9%	11.39B▲ 5.2%	12.01B▲ 5.4%	11.66B▼ 2.9%	11.86B▲ 0%
Asset Turnover	0.32x	0.36x	0.39x	0.36x	0.25x	0.34x	0.34x	0.34x	0.37x	0.39x
Asset Growth %	6.74%	1.56%	6.45%	18%	88.17%	-11.9%	5.15%	5.43%	-2.94%	-11.13%
Total Current Liabilities	293.95M	345.49M	364.49M	653.75M	809.3M	933.19M	1.54B	1.04B	2.24B	2.25B
Accounts Payable	24.37M	40.6M	47.55M	26.95M	100.3M	90.76M	102.75M	77.87M	122.06M	100M
Days Payables Outstanding	80.72	121.93	135.65	66.04	83.06	61.29	86.1	63.77	88.52	106.12
Short-Term Debt	40.6M	33.39M	33.39M	246.32M	31M	31M	604.95M	31M	1.03B	1.03B
Deferred Revenue (Current)	8.62M	5.41M	4.72M	2.55M	2.09M	463K	0	0	0	0
Other Current Liabilities	63.99M	62.51M	85.03M	124.59M	193.1M	169.41M	142.32M	189.76M	1.02B	1.22B
Current Ratio	3.29x	3.57x	4.47x	4.34x	3.23x	2.79x	2.24x	4.46x	1.86x	1.86x
Quick Ratio	3.15x	3.42x	4.26x	4.20x	1.90x	2.03x	1.85x	3.99x	1.67x	1.67x
Cash Conversion Cycle	113.07	88.03	148.73	229	871.73	485.89	481.39	393.97	284.92	380.27
Total Non-Current Liabilities	2.12B	2.1B	2.06B	2.22B	7.52B	6.82B	6.12B	6.88B	5.1B	5.08B
Long-Term Debt	1.54B	1.56B	1.57B	1.85B	6.02B	5.69B	5.11B	6.08B	4.33B	47.3M
Capital Lease Obligations	0	0	151.23M	140.03M	87.2M	71.84M	59.23M	38.94M	50.89M	159.43M
Deferred Tax Liabilities	383.47M	309.1M	224.09M	130.4M	1.3B	944.34M	847.71M	676.74M	594.47M	2.45B
Other Non-Current Liabilities	176.61M	218.88M	109.37M	101.15M	117M	106.81M	104.75M	86.61M	124.52M	4.81B
Total Liabilities	2.41B	2.45B	2.43B	2.88B	8.33B	7.75B	7.66B	7.92B	7.34B	7.33B
Total Debt	1.58B	1.6B	1.77B	2.25B	6.15B	5.81B	5.79B	6.16B	5.42B	1.08B
Net Debt	1.2B	1.29B	1.13B	1.19B	5.56B	4.93B	4.29B	3.75B	4.03B	-766.5M
Debt / Equity	0.58x	0.58x	0.57x	0.61x	1.55x	1.88x	1.55x	1.51x	1.26x	1.26x
Debt / EBITDA	2.28x	1.92x	1.96x	3.43x	8.51x	10.31x	4.76x	4.48x	7.08x	1.08x
Net Debt / EBITDA	1.72x	1.55x	1.26x	1.82x	7.69x	8.74x	3.52x	2.72x	5.26x	5.26x
Interest Coverage	7.89x	9.12x	8.89x	7.68x	1.70x	2.91x	2.80x	3.62x	-2.22x	-3.72x
Total Equity	2.71B▲ 0%	2.76B▲ 1.6%	3.11B▲ 12.8%	3.66B▲ 17.6%	3.97B▲ 8.3%	3.09B▼ 22.2%	3.74B▲ 21.1%	4.09B▲ 9.5%	4.32B▲ 5.5%	4.53B▲ 0%
Equity Growth %	44.52%	1.63%	12.82%	17.64%	8.35%	-22.18%	21.11%	9.55%	5.49%	7.47%
Book Value per Share	44.25	45.04	54.06	64.75	66.43	49.34	51.86	62.02	70.81	68.57
Total Shareholders' Equity	2.71B	2.76B	3.11B	3.66B	3.97B	3.09B	3.74B	4.09B	4.32B	4.53B
Common Stock	61K	61K	61K	61K	61K	61K	61K	61K	6K	0
Retained Earnings	917.96M	841.05M	1.07B	1.16B	830.23M	733.59M	878.66M	1.13B	646.18M	939.2M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-140.88M	-197.79M	-223.39M	-134.35M	-400.36M	-1.13B	-842.15M	-947.67M	-568.6M	-651M
Minority Interest	0	0	0	0	0	0	0	0	0	0

JAZZ Cash Flow Statement

Jazz Pharmaceuticals plc (JAZZ) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	693.09M	798.9M	776.4M	899.65M	778.51M	1.27B	1.09B	1.4B	1.36B	1.36B
Operating CF Margin %	42.82%	42.25%	35.92%	38.06%	25.16%	34.76%	28.48%	34.31%	31.77%	-
Operating CF Growth %	17.37%	15.27%	-2.82%	15.87%	-13.47%	63.39%	-14.15%	27.83%	-2.88%	-68.23%
Net Income	487.85M	447.1M	523.37M	238.62M	-329.67M	-224.06M	414.83M	560.12M	-356.15M	29.49M
Depreciation & Amortization	165.15M	216.73M	370.16M	278.25M	552.48M	629.47M	638.7M	660.07M	696.3M	1.04B
Stock-Based Compensation	106.9M	102.44M	110.56M	121M	189.01M	222M	226.84M	248.04M	291.13M	426.93M
Deferred Taxes	-225.59M	-88.81M	-236.61M	-136.94M	69.2M	-292.25M	-260.22M	-208.33M	-444.97M	-558.11M
Other Non-Cash Items	132.01M	98.16M	159.01M	484.15M	345.44M	926.92M	276.29M	212.72M	1.15B	1.77B
Working Capital Changes	26.77M	23.29M	-150.08M	-85.44M	-47.95M	9.9M	-204.44M	-76.72M	18.9M	-269M
Change in Receivables	12.28M	-40.13M	-92.33M	-38.65M	-92.73M	-90.14M	0	-21.11M	-106.28M	-158.13M
Change in Inventory	-8.67M	-18.51M	-32.79M	-30.54M	-48.86M	-49.64M	0	-45.54M	-86.04M	-12.92M
Change in Payables	214K	17.04M	4.77M	-18.93M	57.02M	-11.22M	9.6M	-20.07M	39.85M	-680K
Cash from Investing	-268.95M	-394.49M	-155.3M	-1.01B	-5.21B	-446.23M	-163.06M	-508.19M	-1.51B	-1.22B
Capital Expenditures	-113.95M	-131.47M	-182.34M	-379.25M	-27.64M	-498.19M	-23.96M	-38.07M	-58.75M	-118.57M
CapEx % of Revenue	7.04%	6.95%	8.43%	16.05%	0.89%	13.61%	0.63%	0.94%	1.38%	-
Acquisitions	85M	111.1M	-142.2M	-364.25M	-6.23B	53M	0	0	-858.05M	-1.72B
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-85M	-63.2M	101.33M	378.51M	-17.89M	0	-19M	-10M	-1.95B	-1.22B
Cash from Financing	-409.11M	-479.13M	-293.75M	528.07M	3.97B	-529.49M	-305.25M	20.52M	-873.38M	-138.41M
Debt Issued (Net)	-326.7M	-25.72M	-33.39M	591.81M	3.87B	-582.01M	-31M	374.77M	-781M	-23.25M
Equity Issued (Net)	-98.8M	-430.33M	-243.62M	-163.41M	0	97.97M	-269.76M	-311.43M	-17.16M	-28.61M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-98.8M	-523.67M	-301.45M	-146.54M	0	-54K	-269.76M	-311.43M	-125.02M	-125.02M
Other Financing	16.39M	-23.08M	-16.74M	99.68M	99.66M	-45.44M	-4.49M	-42.82M	-75.22M	-86.56M
Net Change in Cash	20.07M▲ 0%	-76.41M▼ 480.7%	327.72M▲ 528.9%	420.43M▲ 28.3%	-466.32M▼ 210.9%	290.03M▲ 162.2%	624.83M▲ 115.4%	906.55M▲ 45.1%	-1.02B▼ 212.6%	-97.65M▲ 0%
Free Cash Flow	579.14M▲ 0%	667.43M▲ 15.2%	594.07M▼ 11.0%	520.39M▼ 12.4%	732.98M▲ 40.9%	773.78M▲ 5.6%	1.07B▲ 38.0%	1.35B▲ 26.2%	1.3B▼ 3.8%	1.25B▲ 0%
FCF Margin %	35.78%	35.3%	27.48%	22.02%	23.69%	21.15%	27.86%	33.13%	30.39%	28.06%
FCF Growth %	41.61%	15.25%	-10.99%	-12.4%	40.85%	5.57%	38.03%	26.2%	-3.77%	-16.31%
FCF per Share	9.44	10.90	10.32	9.21	12.28	12.37	14.82	20.42	21.27	21.27
FCF Conversion (FCF/Net Income)	1.42x	1.79x	1.48x	3.77x	-2.37x	-5.68x	2.63x	2.49x	-3.81x	42.23x
Interest Paid	44.61M	42.71M	43M	42.47M	138.27M	270.67M	333.11M	314.82M	0	0
Taxes Paid	174.12M	164.22M	183.61M	226.82M	271.22M	94.68M	177.88M	114.91M	0	0

JAZZ Key Ratios

Jazz Pharmaceuticals plc (JAZZ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	21.25%	16.35%	17.84%	7.05%	-8.63%	-6.36%	12.16%	14.31%	-8.47%	0.71%
Return on Invested Capital (ROIC)	10.65%	11.6%	9.63%	6.23%	1.78%	-0.56%	5.41%	6.78%	2.08%	2.08%
Gross Margin	93.19%	93.57%	94.08%	93.7%	85.76%	85.23%	88.64%	89.05%	88.21%	66.94%
Net Margin	30.14%	23.64%	24.21%	10.1%	-10.63%	-6.12%	10.82%	13.77%	-8.35%	0.66%
Debt / Equity	0.58x	0.58x	0.57x	0.61x	1.55x	1.88x	1.55x	1.51x	1.26x	1.26x
Interest Coverage	7.89x	9.12x	8.89x	7.68x	1.70x	2.91x	2.80x	3.62x	-2.22x	-3.72x
FCF Conversion	1.42x	1.79x	1.48x	3.77x	-2.37x	-5.68x	2.63x	2.49x	-3.81x	42.23x
Revenue Growth	8.79%	16.82%	14.32%	9.34%	30.91%	18.26%	4.78%	6.12%	4.88%	9.2%

JAZZ SEC Filings & Documents

Jazz Pharmaceuticals plc (JAZZ) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 5, 2026·SEC

Material company update

Feb 24, 2026·SEC

Material company update

Jan 12, 2026·SEC

10-K Annual Reports

FY 2026

Feb 24, 2026·SEC

FY 2025

Feb 26, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 5, 2026·SEC

FY 2025

Nov 5, 2025·SEC

FY 2025

Aug 6, 2025·SEC

JAZZ Frequently Asked Questions

Jazz Pharmaceuticals plc (JAZZ) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Jazz Pharmaceuticals plc (JAZZ) reported $4.44B in revenue for fiscal year 2025. This represents a 20601% increase from $21.4M in 2005.

Jazz Pharmaceuticals plc (JAZZ) grew revenue by 4.9% over the past year. Growth has been modest.

Yes, Jazz Pharmaceuticals plc (JAZZ) is profitable, generating $29.5M in net income for fiscal year 2025 (-8.3% net margin).

Dividend & Returns

Jazz Pharmaceuticals plc (JAZZ) has a return on equity (ROE) of -8.5%. Negative ROE indicates the company is unprofitable.

Jazz Pharmaceuticals plc (JAZZ) generated $1.25B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More JAZZ

Jazz Pharmaceuticals plc (JAZZ) financial analysis — history, returns, DCA and operating performance tools

Full JAZZ Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Jazz Pharmaceuticals plc(JAZZ)Earnings, Financials & Key Ratios

JAZZ Key Insights

✓Strengths

✗Weaknesses

JAZZ Price & Volume

JAZZ Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

JAZZ Recent Earnings

JAZZ Peer Comparison

Compare JAZZ vs Peers

vs SUPN

vs CVS

Compare Top 5

JAZZ Income Statement

JAZZ Balance Sheet

JAZZ Cash Flow Statement

JAZZ Key Ratios

JAZZ SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

JAZZ Frequently Asked Questions

Explore More JAZZ

Full JAZZ Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation